## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL						
OMB Number:	3235-028						
Estimated average burden							
hours per response	0						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)													
1. Name and Address of Reporting Person * KELKER NORMAN E				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 03/08/2004						X					
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by More than One Reporting Person Form filed by More than One Reporting Person				
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acqu						Acquired, I	ured, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, i any (Month/Day/Year		Date, if	3. Transaction Code (Instr. 8)		Securities Acqui or Disposed of str. 3, 4 and 5)	red 5. Am Owne Transa	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		neficially (	Ownership of Orm: Direct (D)	Nature Indirect eneficial wnership astr. 4)		
Reminder: I	Report on a so	eparate line for each		- Derivat	tive	Securities	s Acc	Persons in this fo a current	who respond rm are not re- ly valid OMB	quired to re control nu icially Owne	espond u mber.				74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if		4. Transaction Code		er ative es d (A) sed	(Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Options to purchase Common Stock, par value \$.01 per share	\$ 18.32	03/08/2004		A <sup>(1)</sup>		15,000		03/08/2005	03/07/2014	Common Stock, par value \$.01 per share	15,000	\$ 0	15,000 (2	D	

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
KELKER NORMAN E C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022			Senior Vice President			

### **Signatures**

	/s/ Dr. Norman E. Kelker	03/09/2004
_	**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options were granted pursuant to Enzo Biochem, Inc.'s 1999 Stock Option Plan.
- (2) The option vests in four equal annual installments, beginning on March 8, 2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.